Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz

Key Concepts:

• Pharma Tariff Impact
• Domestic vs. Overseas Manufacturing
• Impact on Large Cap vs. Mid/Small Cap Pharma
• Biotech Company Location
• Ten-Year Yields

Pharma Tariff Impact and Market Reaction

The market, including pharma stocks, performed well despite concerns. However, the bond market showed a contrasting trend, with ten-year yields increasing by approximately 19 basis points since the Federal Reserve's rate cut a couple of weeks prior.

Impact on Different Pharma Companies

The discussion focuses on the potential impact of tariffs on pharmaceutical companies, particularly those without U.S. manufacturing facilities. The initial reaction from big pharma stocks was muted, suggesting a limited immediate impact.

Smaller Players and Devastating Impact

Jarrett, the health care strategist at Mizuho, agrees that the tariff impact would likely be more significant for mid- and small-cap pharma companies compared to larger players like Merck, especially those lacking U.S. manufacturing.

Domestic vs. Overseas Manufacturing

The key concern revolves around companies that haven't moved manufacturing to the U.S. The buy-side community expressed concerns about the potential negative impact on companies without domestic manufacturing.

Biotech Companies and Domestic Focus

Most biotech companies followed by Mizuho are primarily domestic, even if they have R&D and development efforts overseas. This domestic focus contributed to the positive market reaction for pharma overall.

Tweet Commentary and Investment in the U.S.

The tweet and subsequent commentary emphasized that companies with facilities and investments in the U.S. would be favored. This further supported the positive sentiment towards pharma companies with a strong domestic presence.

Synthesis/Conclusion

The pharma sector showed resilience despite tariff concerns, largely due to the domestic focus of many biotech companies and the perception that companies investing in U.S. manufacturing would be less affected. However, the potential impact on smaller pharma companies with overseas manufacturing remains a concern. The bond market's reaction, with rising ten-year yields, presents a contrasting economic signal.